BioSpace News Archive

Drug Development

Biohaven’s Rimegepant Positive Phase 3 Trial For Acute Treatment Of Migraine Published In The New England Journal of Medicine

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), announced today that positive results from a Phase 3 pivotal clinical trial of rimegepant, Biohaven’s small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine, are published in the July 12, 2019 issue of the New England Journal of Medicine (NEJM).

July 10, 2019
·
6 min read
BioMidwest

Baxter Supports Advancing American Kidney Health Initiative and Plans Significant U.S. Investment to Help Drive Implementation

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced its full support of the Administration’s Advancing American Kidney Health Initiative introduced today.

July 10, 2019
·
7 min read